A study showed that 86% of patients who took ChemGenex Pharmaceuticals' Omapro were cleared of chronic myeloid leukemia, while 18% of those with early-stage CML showed no signs of the disease in their bone marrow, allowing them to receive a transplant. The findings also affirm Omapro's potential in treating patients who do not respond to Novartis' Gleevec because of a gene mutation.

Full Story:

Related Summaries